← Leaderboards
Michael David Levin
Cavatar, Llc
$2,251,352
Attributed
$2,251,352
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $525K · FY2017–23$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,251,352 · 3
By mechanism
P01$1,676,353 · 1
R41$574,999 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorCaveolaeAntibodiesSolid NeoplasmReagentImmunoconjugatesTechnologyAnimal ModelClinical TranslationImaging AgentEquipmentImageMonoclonal AntibodiesMolecular WeightPharmaceutical PreparationsAntibody ConjugateLung NeoplasmsMedicinePlatinumChemotherapyExperimental StudyInstrumentBlood VesselsClinical Trials
Grant awards (8)
Preclinical Therapeutics Core$232,012
P01 · FY2023 · CA · contact PI
Preclinical Therapeutics Core$232,521
P01 · FY2022 · CA · contact PI
Preclinical Therapeutics Core$370,089
P01 · FY2021 · CA · contact PI
Preclinical Therapeutics Core$399,350
P01 · FY2020 · CA · contact PI
Preclinical Therapeutics Core$442,381
P01 · FY2019 · CA · contact PI
I- Corps Administrative Supplement to Novel Reagents for Breast Tumor SPECT Imaging R41CA217546$50,000
R41 · FY2018 · CA · contact PI
Caveolae-Targeted Cisplatin Immunoconjugates for Effective Lung Cancer Therapy$299,999
R41 · FY2017 · CA · contact PI
Novel Reagents for Breast Tumor SPECT Imaging$225,000
R41 · FY2017 · CA · contact PI